Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

Next Previous
Trial Profile

A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nedosiran (Primary)
  • Indications Primary hyperoxaluria
  • Focus Registrational; Therapeutic Use
  • Acronyms PHYOX 2
  • Sponsors Dicerna Pharmaceuticals

Most Recent Events

  • 02 Oct 2023 According to Novo Nordisk media release, U.S. FDA has approved RivflozaTM for children 9 years of age and older and adults living with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. This approval is based on the results of this trial and interim data from the ongoing phase 3 PHYOXTM3 extension study.
  • 01 Jan 2023 Results assessing the efficacy and safety of nedosiran in primary hyperoxaluria type 1 or 2, published in the Kidney International.
  • 04 Nov 2021 According to a Dicerna media release, Post hoc analysis results from this trial were presented at American Society of Nephrology (ASN) Kidney Week 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top